Checkmate-214 was a randomized phase III trial that established the role of doublet immune checkpoint inhibition (CTLA-4 blockade along with PD-1 inhibition) in ccRCC, which had superior efficacy over sunitinib in the intermediate/poor IMDC risk group [36,41]. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.